- The document discusses recent advances in stroke management including neurorehabilitation, drug development, robotics, cortical stimulation, and stem cell therapies.
- It then discusses various risk factors for ischemic and hemorrhagic stroke, noting that hypertension, diet, physical inactivity, smoking, and abdominal obesity account for the majority of population-attributable risk.
- Specific guidelines and studies are discussed regarding management of hypertension, dyslipidemia, anti-platelet therapy including clopidogrel and aspirin, and LDL cholesterol targets after ischemic stroke to reduce risk of recurrent events.
Tight Glycemic Control Reduces Heart Inflammation And Remodelinghospital
Tight glycemic control through intensive insulin therapy can reduce heart inflammation and remodeling during acute myocardial infarction in hyperglycemic patients by decreasing oxidative stress and inflammation. A study of 88 AMI patients undergoing bypass surgery found that those in the intensive glycemic control group having glucose levels between 80-140 mg/dl had lower heart inflammation and better heart function than those in the conventional control group with levels of 180-200 mg/dl. However, more research is still needed to validate these findings and determine the clinical implications.
- The document discusses secondary prevention of ischemic stroke through the use of antiplatelet agents such as aspirin, ticlopidine, and clopidogrel. These antiplatelet agents provide a modest reduction in risk of non-fatal stroke and death.
- While antiplatelet therapy is effective, more effective and safe treatment options are still needed given the devastating consequences of stroke.
- Acceptable options for initial antiplatelet therapy include aspirin, clopidogrel, ticlopidine, and the combination of aspirin and dipyridamole. Clopidogrel is preferred over ticlopidine due to fewer side effects.
1) The document presents a summary of a presentation on using oral anticoagulants in patients with acute coronary syndrome.
2) It reviews several clinical trials that evaluated adding direct oral anticoagulants to antiplatelet therapy after ACS and found it reduced ischemic events but increased bleeding risk.
3) A meta-analysis of over 29,000 patients from 6 trials found the benefits of adding a DOAC were greater for those with STEMI compared to NSTEMI, with a lower risk of ischemic events outweighing the higher bleeding risk for STEMI patients.
This document discusses strategies for treating dyslipidemia and lowering LDL cholesterol levels. It notes that statins are the primary pharmacological treatment but that many patients do not reach LDL cholesterol goals with statin monotherapy alone. It recommends combining statins with other drugs, such as ezetimibe, which inhibits cholesterol absorption in the gut, or PCSK9 inhibitors. Combination therapy provides complementary mechanisms of action and is more effective at reducing LDL cholesterol than doubling the statin dose alone. Outcome trials show further health benefits from achieving lower LDL levels below currently recommended targets.
1) The CAPRIE trial compared the efficacy and safety of clopidogrel versus aspirin in reducing adverse cardiovascular events in 19,185 patients with clinical manifestations of atherosclerosis.
2) Clopidogrel therapy resulted in a relative risk reduction of 8.7% compared to aspirin therapy in reducing the primary outcome of myocardial infarction, ischemic stroke, or vascular death.
3) Clopidogrel was found to be safer than aspirin, with significantly fewer gastrointestinal hemorrhages, and no significant differences in intracerebral hemorrhages or hemorrhagic deaths.
Tight Glycemic Control Reduces Heart Inflammation And Remodelinghospital
Tight glycemic control through intensive insulin therapy can reduce heart inflammation and remodeling during acute myocardial infarction in hyperglycemic patients by decreasing oxidative stress and inflammation. A study of 88 AMI patients undergoing bypass surgery found that those in the intensive glycemic control group having glucose levels between 80-140 mg/dl had lower heart inflammation and better heart function than those in the conventional control group with levels of 180-200 mg/dl. However, more research is still needed to validate these findings and determine the clinical implications.
- The document discusses secondary prevention of ischemic stroke through the use of antiplatelet agents such as aspirin, ticlopidine, and clopidogrel. These antiplatelet agents provide a modest reduction in risk of non-fatal stroke and death.
- While antiplatelet therapy is effective, more effective and safe treatment options are still needed given the devastating consequences of stroke.
- Acceptable options for initial antiplatelet therapy include aspirin, clopidogrel, ticlopidine, and the combination of aspirin and dipyridamole. Clopidogrel is preferred over ticlopidine due to fewer side effects.
1) The document presents a summary of a presentation on using oral anticoagulants in patients with acute coronary syndrome.
2) It reviews several clinical trials that evaluated adding direct oral anticoagulants to antiplatelet therapy after ACS and found it reduced ischemic events but increased bleeding risk.
3) A meta-analysis of over 29,000 patients from 6 trials found the benefits of adding a DOAC were greater for those with STEMI compared to NSTEMI, with a lower risk of ischemic events outweighing the higher bleeding risk for STEMI patients.
This document discusses strategies for treating dyslipidemia and lowering LDL cholesterol levels. It notes that statins are the primary pharmacological treatment but that many patients do not reach LDL cholesterol goals with statin monotherapy alone. It recommends combining statins with other drugs, such as ezetimibe, which inhibits cholesterol absorption in the gut, or PCSK9 inhibitors. Combination therapy provides complementary mechanisms of action and is more effective at reducing LDL cholesterol than doubling the statin dose alone. Outcome trials show further health benefits from achieving lower LDL levels below currently recommended targets.
1) The CAPRIE trial compared the efficacy and safety of clopidogrel versus aspirin in reducing adverse cardiovascular events in 19,185 patients with clinical manifestations of atherosclerosis.
2) Clopidogrel therapy resulted in a relative risk reduction of 8.7% compared to aspirin therapy in reducing the primary outcome of myocardial infarction, ischemic stroke, or vascular death.
3) Clopidogrel was found to be safer than aspirin, with significantly fewer gastrointestinal hemorrhages, and no significant differences in intracerebral hemorrhages or hemorrhagic deaths.
This document discusses cardiovascular disease (CAD) in South Asians and a clinical trial on the use of statins. It contains the following key points:
1) South Asians have a higher prevalence of CAD than other ethnicities due to genetic and environmental/lifestyle factors such as metabolic syndrome and central obesity.
2) The JUPITER trial found that treating individuals with low LDL cholesterol but high C-reactive protein with rosuvastatin reduced cardiovascular events like heart attack and stroke by 44% compared to placebo, showing statins can benefit those not currently eligible for treatment.
3) Rosuvastatin was well-tolerated in JUPITER and showed no increase in side effects even when LDL
The renin–angiotensin–aldosterone system (RAAS) plays a central role in blood pressure regulation and sodium balance, and its overactivity contributes to conditions like hypertension and heart failure. Inhibition of the RAAS with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) lowers blood pressure and reduces cardiovascular risk. Studies have shown that ACE inhibitors and ARBs can slow the progression of renal disease in patients with diabetes, although their impact on long-term cardiovascular outcomes requires further investigation. The ONTARGET trial found that the ARB telmisartan had comparable reno- and cardioprotective effects as the ACE inhibitor
The TWILIGHT trial compared ticagrelor monotherapy to ticagrelor plus aspirin in patients at high risk of bleeding and ischemic events after PCI. Over 7,000 patients received ticagrelor and aspirin for 3 months after PCI. Then patients were randomized to ticagrelor alone or with aspirin for 12 more months. The study found ticagrelor monotherapy was associated with a 44% lower risk of bleeding over 1 year without increasing ischemic events, suggesting it may be a safer option for high risk patients after a brief initial period of dual antiplatelet therapy.
This document summarizes the key points from a lipidology conference presentation. It discusses recent guidelines and studies on cholesterol treatment, including more aggressive LDL lowering to under 70mg/dl for patients with cardiovascular disease. New tools for general cardiovascular risk prediction were presented. Treatment with high-dose statins was found to significantly reduce stroke recurrence and other outcomes for patients who had a stroke or TIA within the past 1-6 months. Immediate withdrawal of statins after acute stroke was associated with increased risks.
Impact of statins and beta-blocker therapy on mortality after coronary artery...Paul Schoenhagen
Abstract
Background: We conducted a retrospective cohort study of patients after first-time isolated coronary artery bypass graft surgery (CABG) and assessed the impact of a discharge regimen including beta-blockers and statin therapy and their relationship to long-term all cause mortality and major adverse cardiovascular events (MACE).
Methods: We identified patients age >18 years, undergoing first time isolated CABG from 1993 to 2005. Patients were identified using the Cardiovascular Information Registry (CVIR). We collected follow-up information at 30, 60, 90 days and yearly follow-up. The registry is approved for use in research by the institutional review broad.
Results: We identified 5,205 patients who underwent single isolated CABG between January 1993 and December 2005. The mean age was 64.5±9.7 years and over 70% were male. There was a significant difference in the low density lipoproteins (LDL) concentration between those with or without statin medications (134±41.9 mg/dL) (no statin) vs. 126±44.8 mg/dL (with statin), P=0.001. A discharge regimen with statin therapy was associated with and overall reduction in 30 day, 1 year and long-term mortality. In addition, overall the triple ischemic endpoint of death, myocardial infarction (MI) and stroke was also significantly lower in the statin vs. no-statin group. In addition, statin and beta-blockers exerted synergistic effect on overall mortality outcomes short-term and in the long-term. We note that the predictors of overall death include no therapy with statin therapy and age [hazard ratios (HR) 1.1, 95% CI: 1.04-1.078, P<0.001] and presence of renal failure (HR 2.0, P=0.005). The estimated 11-year Kaplan Meier curves for mortality between the two groups starts to diverge immediately post discharge after single isolated CABG and continue to diverge through out the follow-up period.
Conclusions: A post-discharge regimen of statins independently reduces overall and 1 year mortality. These results confirm those of earlier studies within a contemporary surgical population and support the current clinical guidelines.
Impact of statins and beta-blocker therapy on mortality after coronary artery...Paul Schoenhagen
Background: We conducted a retrospective cohort study of patients after first-time isolated coronary artery bypass graft surgery (CABG) and assessed the impact of a discharge regimen including beta-blockers and statin therapy and their relationship to long-term all cause mortality and major adverse cardiovascular events (MACE).
Methods: We identified patients age >18 years, undergoing first time isolated CABG from 1993 to 2005. Patients were identified using the Cardiovascular Information Registry (CVIR). We collected follow-up information at 30, 60, 90 days and yearly follow-up. The registry is approved for use in research by the institutional review broad.
Results: We identified 5,205 patients who underwent single isolated CABG between January 1993 and December 2005. The mean age was 64.5±9.7 years and over 70% were male. There was a significant difference in the low density lipoproteins (LDL) concentration between those with or without statin medications (134±41.9 mg/dL) (no statin) vs. 126±44.8 mg/dL (with statin), P=0.001. A discharge regimen with statin therapy was associated with and overall reduction in 30 day, 1 year and long-term mortality. In addition, overall the triple ischemic endpoint of death, myocardial infarction (MI) and stroke was also significantly lower in the statin vs. no-statin group. In addition, statin and beta-blockers exerted synergistic effect on overall mortality outcomes short-term and in the long-term. We note that the predictors of overall death include no therapy with statin therapy and age [hazard ratios (HR) 1.1, 95% CI: 1.04-1.078, P<0.001] and presence of renal failure (HR 2.0, P=0.005). The estimated 11-year Kaplan Meier curves for mortality between the two groups starts to diverge immediately post discharge after single isolated CABG and continue to diverge through out the follow-up period.
Conclusions: A post-discharge regimen of statins independently reduces overall and 1 year mortality. These results confirm those of earlier studies within a contemporary surgical population and support the current clinical guidelines.
This study aimed to clarify the relationship between lipid profile, morbidity assessed by Killip classification, and 30-day mortality in patients with acute myocardial infarction (AMI). The study found that low-density lipoprotein cholesterol (LDL-C) and triglyceride levels were significantly lower in patients with higher Killip classification (more severe heart failure) and in those who died within 30 days compared to survivors. After adjusting for risk factors, LDL-C less than 62.5 mg/dL and triglycerides less than 110 mg/dL were identified as cutoff values associated with higher 30-day mortality. Patients with both low LDL-C and triglycerides and high Killip classification had a nearly 11-fold
This document discusses antiplatelet therapies and summarizes several studies on their use. It provides guidelines for antiplatelet treatment in different clinical scenarios, such as acute coronary syndrome or stent placement. It also discusses controversies around restarting aspirin after intracerebral hemorrhage and managing dual antiplatelet therapy following a bleed. The document emphasizes the need to balance bleeding risks against risks of stent thrombosis.
The document discusses the concept of "metabolic memory" where the risks of diabetic complications can persist even after glucose levels have returned to normal. It provides evidence from animal and human studies in the 1980s and 2000s supporting this concept. It then summarizes findings from several major clinical trials that compared intensive glucose control to standard control and found reductions in microvascular and macrovascular outcomes with intensive control, though the benefits took years to emerge after trial completion.
The HOPE-3 trial evaluated the effects of rosuvastatin 10 mg daily alone or combined with candesartan/hydrochlorothiazide on cardiovascular outcomes in 12,705 participants without cardiovascular disease at intermediate risk, and found that the combination therapy reduced the primary composite outcome of cardiovascular death, myocardial infarction, or stroke by 29% compared to dual placebo. Significant reductions in LDL cholesterol and blood pressure were seen with combination therapy compared to dual placebo. Adverse events including muscle pain were increased but serious adverse events did not differ significantly between groups.
The guidelines provide recommendations for the secondary prevention of stroke in patients with previous ischemic stroke or transient ischemic attack (TIA). Key recommendations include: aggressively treating hypertension, diabetes, dyslipidemia and other vascular risk factors; initiating antiplatelet therapy; and considering carotid endarterectomy for severe carotid stenosis. Lifestyle modifications such as smoking cessation, weight control, diet and exercise are also encouraged. The guidelines were updated from 1999 based on new clinical trial evidence.
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)Sudhir Kumar
Hypertension is a leading risk factor for stroke. Treating hypertension reduces the risk of stroke through several mechanisms. All classes of antihypertensive drugs lower stroke risk, though some are preferred for primary and secondary stroke prevention. Maintaining controlled blood pressure reduces first and recurrent strokes, highlighting the importance of adherence to antihypertensive regimens. Guidelines recommend targeting a blood pressure of less than 130/80 mmHg to minimize stroke risk, especially for those with additional risk factors.
0900 0920 Antiplatelet and Anticoaulation Therapy Aleti FINAL(1).pptxAdelSALLAM4
This document provides guidelines for antiplatelet and anticoagulation therapy. It discusses:
1) Current practice guidelines for managing antiplatelet therapy in CAD patients, including the selection of different antiplatelet medications and optimal durations of dual antiplatelet therapy.
2) Evidence for aspirin, clopidogrel, prasugrel, and ticagrelor in primary and secondary prevention. It finds prasugrel and ticagrelor reduce ischemic events compared to clopidogrel but with potential for higher bleeding risks.
3) Guidelines for dual antiplatelet therapy duration after stent implantation, recommending at least 1 year for most patients but shorter durations for those at high bleeding risk
The document discusses treatment of hypertensive patients who also have dyslipidemia. It describes a case study of a 57-year-old man with prior myocardial infarction, uncontrolled hypertension, and elevated LDL cholesterol. Clinical trials show that intensive statin therapy to achieve lower LDL levels reduces cardiovascular risks more than moderate statin therapy. The Heart Protection Study also found that simvastatin reduced cardiovascular events in high-risk patients, regardless of baseline LDL level.
Bleeding complications in secondary stroke prevention by antiplatelet therapy...Duwan Arismendy
Abstract
Abstract. Boysen G (University of Copenhagen, Copenhagen, Denmark). Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit–risk analysis (Review). J Intern Med 1999; 246: 239–245.
This review analyses the benefit–risk ratio of antiplatelet drugs in secondary stroke prevention and is based on the published data from eight large stroke prevention trials. In patients with prior transient ischaemic attack (TIA) or stroke, aspirin prevented one to two vascular events (stroke, AMI, or vascular death) per 100 treatment-years with an excess risk of fatal and severe bleeds of 0.4–0.6 per 100 treatment-years. The gastrointestinal bleeding risk was significantly lower with ticlopidine and clopidogrel, which were both somewhat more effective than aspirin in the prevention of vascular events. The combination of dipyridamole and aspirin prevented 2.82 strokes at the expense of an excess risk of 0.61 (95% CI = 0.27–0.95) fatal or severe bleeds per 100 treatment-years.
In the acute phase of stroke, the aspirin-associated risk of haemorrhagic complications was much increased compared with that in the stable phase after stroke, with 0.48 (95% CI = 0.13–0.83) fatal or severe bleeds per 100 treated patients for the first 4 weeks after stroke in the Chinese Acute Stroke Trial and 0.41 (95% CI = 0.05–0.77) in the International Stroke Trial. Still, there was a net benefit with the prevention of about one death or non-fatal ischaemic stroke per 100 treated patients.
This document discusses the management of hypertension to prevent cardiovascular events. It provides global statistics showing that hypertension is a leading cause of death worldwide. It then discusses the prevalence of hypertension, cardiovascular risk factors, target organ damage, and the link between hypertension and coronary heart disease. It reviews evidence from clinical trials on lifestyle modifications, adherence, early and aggressive blood pressure lowering, treating to target levels, and choice of drugs to prevent cardiovascular events in hypertensive patients.
Evolocumab and its clinical outcomes in patients of cardiovascular diseasetarun kumar
This document summarizes a journal club presentation on a clinical trial investigating the PCSK9 inhibitor evolocumab. The trial found that adding evolocumab to statin therapy in patients with cardiovascular disease reduced LDL cholesterol by 59% on average and reduced the risk of the primary composite cardiovascular endpoint of death, heart attack, stroke or revascularization by 15% and the secondary composite of just death, heart attack or stroke by 20% over a median follow up of 26 months. Evolocumab demonstrated a safety profile similar to placebo with no significant differences in adverse events. This trial provides evidence that further lowering of LDL cholesterol beyond standard statin therapy provides cardiovascular benefit.
The SPARCL trial investigated whether high-dose atorvastatin (80 mg daily) could reduce the risk of fatal or non-fatal stroke in patients who had a stroke or transient ischemic attack 1-6 months prior and no history of coronary heart disease. The double-blind randomized controlled trial assigned 4731 eligible patients to atorvastatin or placebo groups. After a median follow-up of 4.9 years, treatment with atorvastatin reduced the risk of fatal or non-fatal stroke by 2% compared to placebo, with a number needed to treat of 53. Atorvastatin also reduced the risk of major cardiovascular events by 18% compared to placebo.
Cervical spondylotic myelopathy is caused by the degeneration of cervical spinal elements like discs and bones. This leads to static factors like osteophyte growth and ligament thickening that reduce the spinal canal diameter. Dynamic factors during neck movement also compress the spinal cord. Over time, this causes pathological changes in the spinal cord like demyelination and nerve fiber damage. Vascular changes from arterial compression can further injure the spinal cord. Together, these mechanical and ischemic mechanisms result in the neurological symptoms seen in cervical spondylotic myelopathy.
This document discusses operative management of cervical degenerative disease. It covers indications and contraindications for various surgical approaches including anterior, posterior, and combined approaches. Anterior approaches like anterior cervical discectomy and fusion are used for single or two level disease anteriorly. Posterior approaches like laminectomy and laminoplasty are used for multilevel disease or posterior compression. Factors like location of compression, number of levels, alignment, and instability are considered in surgical planning. Complications of each approach and factors affecting prognosis are also summarized.
This document discusses cardiovascular disease (CAD) in South Asians and a clinical trial on the use of statins. It contains the following key points:
1) South Asians have a higher prevalence of CAD than other ethnicities due to genetic and environmental/lifestyle factors such as metabolic syndrome and central obesity.
2) The JUPITER trial found that treating individuals with low LDL cholesterol but high C-reactive protein with rosuvastatin reduced cardiovascular events like heart attack and stroke by 44% compared to placebo, showing statins can benefit those not currently eligible for treatment.
3) Rosuvastatin was well-tolerated in JUPITER and showed no increase in side effects even when LDL
The renin–angiotensin–aldosterone system (RAAS) plays a central role in blood pressure regulation and sodium balance, and its overactivity contributes to conditions like hypertension and heart failure. Inhibition of the RAAS with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) lowers blood pressure and reduces cardiovascular risk. Studies have shown that ACE inhibitors and ARBs can slow the progression of renal disease in patients with diabetes, although their impact on long-term cardiovascular outcomes requires further investigation. The ONTARGET trial found that the ARB telmisartan had comparable reno- and cardioprotective effects as the ACE inhibitor
The TWILIGHT trial compared ticagrelor monotherapy to ticagrelor plus aspirin in patients at high risk of bleeding and ischemic events after PCI. Over 7,000 patients received ticagrelor and aspirin for 3 months after PCI. Then patients were randomized to ticagrelor alone or with aspirin for 12 more months. The study found ticagrelor monotherapy was associated with a 44% lower risk of bleeding over 1 year without increasing ischemic events, suggesting it may be a safer option for high risk patients after a brief initial period of dual antiplatelet therapy.
This document summarizes the key points from a lipidology conference presentation. It discusses recent guidelines and studies on cholesterol treatment, including more aggressive LDL lowering to under 70mg/dl for patients with cardiovascular disease. New tools for general cardiovascular risk prediction were presented. Treatment with high-dose statins was found to significantly reduce stroke recurrence and other outcomes for patients who had a stroke or TIA within the past 1-6 months. Immediate withdrawal of statins after acute stroke was associated with increased risks.
Impact of statins and beta-blocker therapy on mortality after coronary artery...Paul Schoenhagen
Abstract
Background: We conducted a retrospective cohort study of patients after first-time isolated coronary artery bypass graft surgery (CABG) and assessed the impact of a discharge regimen including beta-blockers and statin therapy and their relationship to long-term all cause mortality and major adverse cardiovascular events (MACE).
Methods: We identified patients age >18 years, undergoing first time isolated CABG from 1993 to 2005. Patients were identified using the Cardiovascular Information Registry (CVIR). We collected follow-up information at 30, 60, 90 days and yearly follow-up. The registry is approved for use in research by the institutional review broad.
Results: We identified 5,205 patients who underwent single isolated CABG between January 1993 and December 2005. The mean age was 64.5±9.7 years and over 70% were male. There was a significant difference in the low density lipoproteins (LDL) concentration between those with or without statin medications (134±41.9 mg/dL) (no statin) vs. 126±44.8 mg/dL (with statin), P=0.001. A discharge regimen with statin therapy was associated with and overall reduction in 30 day, 1 year and long-term mortality. In addition, overall the triple ischemic endpoint of death, myocardial infarction (MI) and stroke was also significantly lower in the statin vs. no-statin group. In addition, statin and beta-blockers exerted synergistic effect on overall mortality outcomes short-term and in the long-term. We note that the predictors of overall death include no therapy with statin therapy and age [hazard ratios (HR) 1.1, 95% CI: 1.04-1.078, P<0.001] and presence of renal failure (HR 2.0, P=0.005). The estimated 11-year Kaplan Meier curves for mortality between the two groups starts to diverge immediately post discharge after single isolated CABG and continue to diverge through out the follow-up period.
Conclusions: A post-discharge regimen of statins independently reduces overall and 1 year mortality. These results confirm those of earlier studies within a contemporary surgical population and support the current clinical guidelines.
Impact of statins and beta-blocker therapy on mortality after coronary artery...Paul Schoenhagen
Background: We conducted a retrospective cohort study of patients after first-time isolated coronary artery bypass graft surgery (CABG) and assessed the impact of a discharge regimen including beta-blockers and statin therapy and their relationship to long-term all cause mortality and major adverse cardiovascular events (MACE).
Methods: We identified patients age >18 years, undergoing first time isolated CABG from 1993 to 2005. Patients were identified using the Cardiovascular Information Registry (CVIR). We collected follow-up information at 30, 60, 90 days and yearly follow-up. The registry is approved for use in research by the institutional review broad.
Results: We identified 5,205 patients who underwent single isolated CABG between January 1993 and December 2005. The mean age was 64.5±9.7 years and over 70% were male. There was a significant difference in the low density lipoproteins (LDL) concentration between those with or without statin medications (134±41.9 mg/dL) (no statin) vs. 126±44.8 mg/dL (with statin), P=0.001. A discharge regimen with statin therapy was associated with and overall reduction in 30 day, 1 year and long-term mortality. In addition, overall the triple ischemic endpoint of death, myocardial infarction (MI) and stroke was also significantly lower in the statin vs. no-statin group. In addition, statin and beta-blockers exerted synergistic effect on overall mortality outcomes short-term and in the long-term. We note that the predictors of overall death include no therapy with statin therapy and age [hazard ratios (HR) 1.1, 95% CI: 1.04-1.078, P<0.001] and presence of renal failure (HR 2.0, P=0.005). The estimated 11-year Kaplan Meier curves for mortality between the two groups starts to diverge immediately post discharge after single isolated CABG and continue to diverge through out the follow-up period.
Conclusions: A post-discharge regimen of statins independently reduces overall and 1 year mortality. These results confirm those of earlier studies within a contemporary surgical population and support the current clinical guidelines.
This study aimed to clarify the relationship between lipid profile, morbidity assessed by Killip classification, and 30-day mortality in patients with acute myocardial infarction (AMI). The study found that low-density lipoprotein cholesterol (LDL-C) and triglyceride levels were significantly lower in patients with higher Killip classification (more severe heart failure) and in those who died within 30 days compared to survivors. After adjusting for risk factors, LDL-C less than 62.5 mg/dL and triglycerides less than 110 mg/dL were identified as cutoff values associated with higher 30-day mortality. Patients with both low LDL-C and triglycerides and high Killip classification had a nearly 11-fold
This document discusses antiplatelet therapies and summarizes several studies on their use. It provides guidelines for antiplatelet treatment in different clinical scenarios, such as acute coronary syndrome or stent placement. It also discusses controversies around restarting aspirin after intracerebral hemorrhage and managing dual antiplatelet therapy following a bleed. The document emphasizes the need to balance bleeding risks against risks of stent thrombosis.
The document discusses the concept of "metabolic memory" where the risks of diabetic complications can persist even after glucose levels have returned to normal. It provides evidence from animal and human studies in the 1980s and 2000s supporting this concept. It then summarizes findings from several major clinical trials that compared intensive glucose control to standard control and found reductions in microvascular and macrovascular outcomes with intensive control, though the benefits took years to emerge after trial completion.
The HOPE-3 trial evaluated the effects of rosuvastatin 10 mg daily alone or combined with candesartan/hydrochlorothiazide on cardiovascular outcomes in 12,705 participants without cardiovascular disease at intermediate risk, and found that the combination therapy reduced the primary composite outcome of cardiovascular death, myocardial infarction, or stroke by 29% compared to dual placebo. Significant reductions in LDL cholesterol and blood pressure were seen with combination therapy compared to dual placebo. Adverse events including muscle pain were increased but serious adverse events did not differ significantly between groups.
The guidelines provide recommendations for the secondary prevention of stroke in patients with previous ischemic stroke or transient ischemic attack (TIA). Key recommendations include: aggressively treating hypertension, diabetes, dyslipidemia and other vascular risk factors; initiating antiplatelet therapy; and considering carotid endarterectomy for severe carotid stenosis. Lifestyle modifications such as smoking cessation, weight control, diet and exercise are also encouraged. The guidelines were updated from 1999 based on new clinical trial evidence.
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)Sudhir Kumar
Hypertension is a leading risk factor for stroke. Treating hypertension reduces the risk of stroke through several mechanisms. All classes of antihypertensive drugs lower stroke risk, though some are preferred for primary and secondary stroke prevention. Maintaining controlled blood pressure reduces first and recurrent strokes, highlighting the importance of adherence to antihypertensive regimens. Guidelines recommend targeting a blood pressure of less than 130/80 mmHg to minimize stroke risk, especially for those with additional risk factors.
0900 0920 Antiplatelet and Anticoaulation Therapy Aleti FINAL(1).pptxAdelSALLAM4
This document provides guidelines for antiplatelet and anticoagulation therapy. It discusses:
1) Current practice guidelines for managing antiplatelet therapy in CAD patients, including the selection of different antiplatelet medications and optimal durations of dual antiplatelet therapy.
2) Evidence for aspirin, clopidogrel, prasugrel, and ticagrelor in primary and secondary prevention. It finds prasugrel and ticagrelor reduce ischemic events compared to clopidogrel but with potential for higher bleeding risks.
3) Guidelines for dual antiplatelet therapy duration after stent implantation, recommending at least 1 year for most patients but shorter durations for those at high bleeding risk
The document discusses treatment of hypertensive patients who also have dyslipidemia. It describes a case study of a 57-year-old man with prior myocardial infarction, uncontrolled hypertension, and elevated LDL cholesterol. Clinical trials show that intensive statin therapy to achieve lower LDL levels reduces cardiovascular risks more than moderate statin therapy. The Heart Protection Study also found that simvastatin reduced cardiovascular events in high-risk patients, regardless of baseline LDL level.
Bleeding complications in secondary stroke prevention by antiplatelet therapy...Duwan Arismendy
Abstract
Abstract. Boysen G (University of Copenhagen, Copenhagen, Denmark). Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit–risk analysis (Review). J Intern Med 1999; 246: 239–245.
This review analyses the benefit–risk ratio of antiplatelet drugs in secondary stroke prevention and is based on the published data from eight large stroke prevention trials. In patients with prior transient ischaemic attack (TIA) or stroke, aspirin prevented one to two vascular events (stroke, AMI, or vascular death) per 100 treatment-years with an excess risk of fatal and severe bleeds of 0.4–0.6 per 100 treatment-years. The gastrointestinal bleeding risk was significantly lower with ticlopidine and clopidogrel, which were both somewhat more effective than aspirin in the prevention of vascular events. The combination of dipyridamole and aspirin prevented 2.82 strokes at the expense of an excess risk of 0.61 (95% CI = 0.27–0.95) fatal or severe bleeds per 100 treatment-years.
In the acute phase of stroke, the aspirin-associated risk of haemorrhagic complications was much increased compared with that in the stable phase after stroke, with 0.48 (95% CI = 0.13–0.83) fatal or severe bleeds per 100 treated patients for the first 4 weeks after stroke in the Chinese Acute Stroke Trial and 0.41 (95% CI = 0.05–0.77) in the International Stroke Trial. Still, there was a net benefit with the prevention of about one death or non-fatal ischaemic stroke per 100 treated patients.
This document discusses the management of hypertension to prevent cardiovascular events. It provides global statistics showing that hypertension is a leading cause of death worldwide. It then discusses the prevalence of hypertension, cardiovascular risk factors, target organ damage, and the link between hypertension and coronary heart disease. It reviews evidence from clinical trials on lifestyle modifications, adherence, early and aggressive blood pressure lowering, treating to target levels, and choice of drugs to prevent cardiovascular events in hypertensive patients.
Evolocumab and its clinical outcomes in patients of cardiovascular diseasetarun kumar
This document summarizes a journal club presentation on a clinical trial investigating the PCSK9 inhibitor evolocumab. The trial found that adding evolocumab to statin therapy in patients with cardiovascular disease reduced LDL cholesterol by 59% on average and reduced the risk of the primary composite cardiovascular endpoint of death, heart attack, stroke or revascularization by 15% and the secondary composite of just death, heart attack or stroke by 20% over a median follow up of 26 months. Evolocumab demonstrated a safety profile similar to placebo with no significant differences in adverse events. This trial provides evidence that further lowering of LDL cholesterol beyond standard statin therapy provides cardiovascular benefit.
The SPARCL trial investigated whether high-dose atorvastatin (80 mg daily) could reduce the risk of fatal or non-fatal stroke in patients who had a stroke or transient ischemic attack 1-6 months prior and no history of coronary heart disease. The double-blind randomized controlled trial assigned 4731 eligible patients to atorvastatin or placebo groups. After a median follow-up of 4.9 years, treatment with atorvastatin reduced the risk of fatal or non-fatal stroke by 2% compared to placebo, with a number needed to treat of 53. Atorvastatin also reduced the risk of major cardiovascular events by 18% compared to placebo.
Cervical spondylotic myelopathy is caused by the degeneration of cervical spinal elements like discs and bones. This leads to static factors like osteophyte growth and ligament thickening that reduce the spinal canal diameter. Dynamic factors during neck movement also compress the spinal cord. Over time, this causes pathological changes in the spinal cord like demyelination and nerve fiber damage. Vascular changes from arterial compression can further injure the spinal cord. Together, these mechanical and ischemic mechanisms result in the neurological symptoms seen in cervical spondylotic myelopathy.
This document discusses operative management of cervical degenerative disease. It covers indications and contraindications for various surgical approaches including anterior, posterior, and combined approaches. Anterior approaches like anterior cervical discectomy and fusion are used for single or two level disease anteriorly. Posterior approaches like laminectomy and laminoplasty are used for multilevel disease or posterior compression. Factors like location of compression, number of levels, alignment, and instability are considered in surgical planning. Complications of each approach and factors affecting prognosis are also summarized.
This document summarizes information about anterior communicating artery aneurysms. It discusses that they are the most common site for aneurysms, can bleed in young people, and generally require surgery for treatment. It also notes that clipping is better than coiling for these aneurysms due to the high risk of surgery from their proximity to important brain structures. The document provides details on the circle of Willis, segments of the anterior cerebral artery, branches, recurrent artery of Heubner, anterior communicating artery variations, and surgical approaches for different aneurysm projections.
Modern aneurysm clips have evolved significantly from early malleable silver clips. There are now several standardized clip designs made of improved materials like titanium. Clips are classified by size, shape, and mechanism. Temporary clips are softer than permanent clips. Successful clipping requires careful planning and dissection to fully expose the aneurysm neck. The appropriate clip type, size, shape, and orientation depends on the specific aneurysm location and configuration.
Benign intracranial hypertension (BIH), also known as idiopathic intracranial hypertension or pseudotumor cerebri, is characterized by increased intracranial pressure without a tumor or other identifiable cause. Common symptoms include headache, nausea, visual disturbances, and papilledema which can cause vision loss if untreated. While the exact cause is unknown, theories include excess CSF production, increased blood flow to the brain, or impaired venous drainage from the brain. Treatment involves weight loss, medications like acetazolamide, and sometimes surgical procedures to relieve pressure like optic nerve sheath fenestration or CSF shunting.
Benign intracranial hypertension (BIH), also known as idiopathic intracranial hypertension or pseudotumor cerebri, is characterized by increased intracranial pressure without a tumor or other identifiable cause. Common symptoms include headache, nausea, visual disturbances, and papilledema which can cause vision loss if untreated. While the exact cause is unknown, theories include excess CSF production, increased blood flow to the brain, or impaired venous drainage from the brain. Treatment involves weight loss, medications like acetazolamide, and sometimes surgical procedures to relieve pressure like optic nerve sheath fenestration or CSF shunting.
1. The document discusses the neurologic control of the urinary system, including the pathways involved in storage and voiding of urine and the effects of lesions along these pathways.
2. It describes how lesions in different areas can result in conditions like urinary frequency, retention, or obstructed voiding and discusses the clinical presentations of different neurogenic bladder disorders.
3. The pathways discussed include the cerebral, cord, urethral, and detrusor reflex loops which coordinate the bladder and sphincter during the storage and voiding phases of micturition.
The pineal gland is a small structure located in the center of the brain near the quadrigeminal cistern. It is supplied by arteries from the posterior circulation and drained by veins. The infratentorial supra cerebellar approach is described for accessing tumors of the pineal gland. This approach involves a midline incision, craniotomy above the torcula and transverse sinus, and dural incision between the transverse sinuses to retract the cerebellum and tentorium and expose the pineal region.
Traumatic cerebrospinal fluid (CSF) fistulas occur when there is a tear in the dura and arachnoid, often associated with a skull base fracture communicating with the nasal cavity, sinuses, or middle ear. CSF leaks can be caused by blunt or penetrating injuries to the anterior, middle, or posterior cranial fossa. Clinical features include nasal discharge, salty taste, ear fullness, and 'reservoir sign' of fluid draining from the nose or ear with head position changes. Diagnosis involves identifying CSF through glucose or chlorine levels. CT and MRI are used to locate the fistula. Management includes antibiotics if infected, bed rest, and usually early surgical repair either endoscop
This document summarizes information about anterior communicating artery aneurysms. It discusses that they are the most common site for aneurysms, can bleed in young people, and generally require surgery for treatment. It also notes that clipping is better than coiling for these aneurysms due to the high risk of surgery from their proximity to important brain structures. The document provides details on the circle of Willis, segments of the anterior cerebral artery, branches, recurrent artery of Heubner, anterior communicating artery variations, and surgical approaches for different aneurysm projections.
Intracranial aneurysms are focal dilatations of blood vessels in the brain that are prone to rupture and cause subarachnoid hemorrhage. The most common type is saccular aneurysms located at vessel junctions or branch points. Ruptured aneurysms present with sudden severe headache, neck stiffness, nausea/vomiting, and sometimes altered consciousness. Diagnosis is made using CT or MRI of the brain along with CT or catheter angiography. Treatment involves surgery such as clipping or endovascular coiling to prevent further rupture as well as managing complications like vasospasm.
Modern aneurysm clips have evolved significantly from early malleable silver clips. There are now several designs of permanent and temporary clips made from improved materials like titanium. Different clip shapes, sizes, and special features allow neurosurgeons to precisely clip various aneurysm types in optimal configurations. Careful planning and dissection are needed to safely apply clips and completely exclude aneurysms.
The cervical spine anatomy summary is as follows:
1) The cervical spine consists of 7 vertebrae that support the head and allow for movement. It contains bony structures like the vertebral bodies and ligaments that provide stability.
2) The atlas (C1) and axis (C2) have unique structures that facilitate rotation. The atlas supports the head and allows for flexion and extension while the axis provides most axial rotation through its odontoid process.
3) Intervertebral discs composed of the nucleus pulposus and annulus fibrosus act as shock absorbers between vertebrae. Along with facet joints and ligaments, they maintain stability while allowing motion.
This document summarizes three cranial nerves: the oculomotor nerve (CN III), trochlear nerve (CN IV), and abducens nerve (CN VI). It outlines key functions and clinical findings for each nerve, including specific eye movements, pupil responses, and neurological deficits. It also describes different levels of injury (nuclear, fascicular, etc.) and potential causes of damage like uncal herniation or vascular issues. Testing maneuvers are mentioned for localizing trochlear nerve injuries.
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
How to Control Your Asthma Tips by gokuldas hospital.Gokuldas Hospital
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
2. STROKE MANAGEMENT STRATEGIES
Neurorehabilitation
Drug development
Robotics
Cortical stimulation
Stem cell therapies
V. Neuroprotection and Repair
Anti-excitability
Anti-inflammatory
Anti-apoptosis
Promote repair
Neuroplasticity
Recovery
3. RISK FACTORS
The risk of recurrent stroke or TIA is high but can be mitigated with appropriate
secondary stroke prevention.
5 factors—BP,
diet,
physical inactivity,
smoking
abdominal obesity-
accounted for 82% and 90% of the population-attributable risk for ischemic and
hemorrhagic stroke in the INTERSTROKE study (Global and regional effects of
potentially modifiable risk factors associated with acute stroke
in 32 countries).
Global Burden of Disease Study showed that 90.5% of the global burden of
stroke was attributable to modifiable risk factors
4. TABLE 65.1 Risk Factors for Ischemic Stroke
Nonmodifiable Modifiable
Age
Gender
Race
Family
history
Genetics
Arterial hypertension
Transient ischemic attacks
Prior stroke
Asymptomatic carotid bruit/stenosis
Cardiac disease
Aortic arch atheromatosis
Diabetes mellitus
Dyslipidemia
Cigarette smoking
Alcohol consumption
Increased fibrinogen
Elevated homocysteine
Lack of physical activity
Low serum folate
Elevated anticardiolipin antibodies
Oral contraceptive use
Obesity
5. 1. HYPERTENSION
TABLE 65.2 ACC/AHA 2017 Guideline for the Management of High Blood Pressure in Secondary
Stroke Prevention in Adult Patients
Population BP Goal Agents and Timing of Therapy
Adult with
stroke or TIA SBP <130
• Thiazide-type diuretic (preferably a
long-acting agent), ACE-I or ARB. or in
DBP <80 long term) Combination
• Restart anti-HTN medication a few days after
the index event for patients previously on
medication
• For patients not previously on drugs with
established BP >140 mm Hg or DBP > 90 mm
Hg start therapy a few days after event
• For patients not previously treated with SBP
<140 mmHg or DBP <90 mm Hg the benefit of
anti-HTN drugs is less clear
AHA/ASA 2021 GUIDELINES ON STROKE PREVENTION
6. 2. DYSLIPIDEMIA
Dyslipidemia is a recognized risk factor for ischemic stroke.
Ischemic stroke risk increases with increasing serum cholesterol, and the
reduction in stroke risk associated with 3-hydroxy, 3-methyl-glutaryl
coenzyme A reductase inhibitor (statin) therapies is related to reduction in
LDL.
Lipid-lowering agents may slow atherosclerotic plaque progression and may
even cause plaque regression.
7. TRAILS
1. The Myocardial Ischemia Reduction with Aggressive Cholesterol
Lowering (MIRACL) showed a 50% relative risk reduction in stroke
among high-risk coronary disease patients
2. The Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm
(ASCOT-LLA) study demonstrated a favorable trend for fatal and nonfatal
stroke, with a 27% RRR in patients at low risk for coronary events
3. The Heart Protection Study (HPS) of patients at high risk with DM, coronary
artery disease, or other atherosclerotic vascular disease showed an overall
reduction in stroke risk
8. A Comparison of Two LDL Cholesterol Targets
after Ischemic Stroke
P. Amarenco, J.S. Kim, J. Labreuche, H. Charles, J. Abtan, Y. B£jot, L. Cabrejo,J.-K. Cha, G. Ducrocq, M. Giroud, C. Guidoux,
C. Hobeanu, Y.-J. Kim, B. Lapergue, P.C. Lavall^e, B.-C. Lee, K.-B. Lee, D. Leys, M.-H. Mahagne,
E. Meseguer, N. Nighoghossian, F. Pico, Y. Samson, I. Sibon, P.G. Steg, S.-M. Sung, P.-J. Touboul, E. Touz6, O. Varenne, £.
Vicaut. N. Yelles. and E. Bruckert. for the Treat Stroke to Target Investigators*
5.TREAT
STROKE TO
TARGET
BACKGROUND
The use of intensive lipid-lowering therapy by means of statin medications is recommended after transient ischemic attack (TIA) and
ischemic stroke of atherosclerotic origin. The target level for low-density lipoprotein (LDL) cholesterol to reduce cardiovascular events after
stroke has not been well studied
METHODS
In this parallel-group trial conducted in France and South Korea, we randomly assigned patients with ischemic stroke in the previous 3
months or a TIA within the previous 15 days to a target LDL cholesterol level of less than 70 mg per deciliter (1.8 mmol per liter) (lower-
target group) or to a target range of 90 mg to 110 mg per deciliter (2.3 to 2.8 mmol per liter) (higher-target group). All the patients had
evidence of cerebrovascular or coronary-artery atherosclerosis and received a statin, ezetimibe, or both. The composite primary end point of
major cardiovascular events included ischemic stroke, myocardial infarction, new symptoms leading to urgent coronary or carotid
revascularization, or death from cardiovascular causes.
RESULTS
A total of2860 patients were enrolled and followed for a median of 3.5 years; 1430 were assigned to each LDL cholesterol target group. The
mean LDL cholesterol level at baseline was 135 mg per deciliter (3.5 mmol per liter), and the mean achieved LDL cholesterol level was 65
mg per deciliter (1.7 mmol per liter) in the lower-target group and 96 mg per deciliter (2.5 mmol per liter) in the higher-target group. The trial
was stopped for administrative reasons after 277 of an anticipated 385 end-point events had occurred. The composite primary end point
occurred in 121 patients (8.5%) in the lower-target group and in 156 (10.9%) in the higher-target group (adjusted hazard ratio, 0.78; 95%
confidence interval, 0.61 to 0.98; P=0.04). The incidence of intracranial hemorrhage and newly diagnosed diabetes did not differ significantly
between the two groups.
CONCLUSIONS
After an ischemic stroke or TIA with evidence of atherosclerosis, patients
who had a target LDL cholesterol level of less than 70 mg per deciliter had a
lower risk of subsequent cardiovascular events than those who had a target
range of 90 mg to 110 mg per deciliter.
10. Clopidogrel with Aspirin in Acute Minor Stroke
CHANCE TRIAL
2013
BACKGROUND
Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke.
Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than
aspirin alone.
METHODS
In a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned
5170 patients within 24 hours after the onset of minor ischemic stroke or high-risk TIA to combination therapy with
clopidogrel and aspirin (clopidogrel at an initial dose of 300 mg, followed by 75 mg per day for 90 days, plus aspirin
at a dose of 75 mg per day for the first 21 days) or to placebo plus aspirin (75 mg per day for 90 days). All
participants received open-label aspirin at a clinician-determined dose of 75 to 300 mg on day 1. The primary
outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis.
Treatment differences were assessed with the use of a Cox proportional-hazards model, with study center as a random
effect.
RESULTS
Stroke occurred in 8.2%> of patients in the clopidogrel-aspirin group, as compared with 11.7% of those in the aspirin
group (hazard ratio, 0.68; 95% confidence interval, 0.57 to 0.81; P<0.001). Moderate or severe hemorrhage occurred
in seven patients (0.3%) in the clopidogrel-aspirin group and in eight (0.3%) in the aspirin group (P=0.73); the rate of
hemorrhagic stroke was 0.3% in each group.
CONCLUSIONS
Among patients with TIA or minor stroke who can be treated within 24
hours after the onset of symptoms, the combination of clopidogrel and
aspirin is superior to aspirin alone for reducing the risk of stroke in the
first 90 days and does not increase the risk of hemorrhage.
11. Platelet-
Oriented
Inhibition in
New TIA
and Minor
Ischemic
Stroke
(POINT)
trial 2018
Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a
minor ischemic stroke or transient ischemic attack (TIA). A trial of combination antiplatelet therapy in a Chinese population has shown a
reduction in the risk of recurrent stroke. We tested this combination in an international population.
METHODS
In a randomized trial, we assigned patients with minor ischemic stroke or high-risk TIA to receive either clopidogrel at a loading dose of
600 mg on day 1, followed by 75 mg per day, plus aspirin (at a dose of 50 to 325 mg per day) or the same range of doses of aspirin alone.
The dose of aspirin in each group was selected by the site investigator. The primary efficacy outcome in a time-to-event analysis was the
risk of a composite of major ischemic events, which was defined as ischemic stroke, myocardial infarction, or death from an ischemic
vascular event, at 90 days.
RESULTS
A total of 4881 patients were enrolled at 269 international sites. The trial was halted after 84% of the anticipated number of patients had
been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated
with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days. Major ischemic
events occurred in 121 of 2432 patients (5.0%) receiving clopidogrel plus aspirin and in 160 of 2449 patients (6.5%) receiving aspirin plus
placebo (hazard ratio, 0.75; 95% confidence interval [Cl],
0.59 to 0.95; P=0.02), with most events occurring during the first week after the initial event. Major hemorrhage occurred in 23 patients
(0.9%) receiving clopidogrel plus aspirin and in 10 patients (0.4%) receiving aspirin plus placebo (hazard ratio, 2.32; 95% Cl, 1.10 to
4.87; P=0.02).
CONCLUSIONS
In patients with minor ischemic stroke or high-risk TIA, those who received a
combination of clopidogrel and aspirin had a lower risk of major ischemic events but
a higher risk of major hemorrhage at 90 days than those who received aspirin alone.
12. Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke
An Exploratory Analysis of the THALES Randomized Clinical Trial 2020
IMPORTANCE Pnor trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These patients were included in the Acute
Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial,
but results have not been reported separately, raising concerns about safety and efficacy in this subgroup.
OBJECTIVE To evaluate the efficacy and safety of ticagrelor plus aspirin in patients with moderate ischemic stroke (National Institutes of Health
Stroke Scale [NIHSS] score of 4 to 5).
DESIGN. SETTING, AND PARTICIPANTS The THALES trial was a randomized trial conducted at 414 hospitals in 28 countries in January 2018 and
December 2019. This exploratory analysis compared patients with moderate stroke (baseline NIHSS score of 4 to 5) with patients with less
severe stroke (NIHSS score of 0 to 3). A total of 9983 patients with stroke were included in the present analysis, after excluding 2 patients with
NIHSS scores greater than 5 and 1031 patients with transient ischemic attack. Data were analyzed from March to April 2021.
INTERVENTIONS Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily on days 2 to 30) or placebo within 24 hours after
symptom onset. All patients received aspinn,
300 to 325 mg. on day 1 followed by aspirin. 75 to 100 mg. daily on days 2 to 30. Patients were observed for 30 additional days.
MAIN OUTCOMES AND MEASURES The primary outcome was time to stroke or death within 30 days. The primary safety outcome was time to severe
bleeding.
RESULTS In total, 3312 patients presented with moderate stroke and 6671 presented with less severe stroke. Of those in the moderate stroke
group. 1293 (39.0%) were female, and the mean (SD) age was 645 (10.8) years: of those in the less severe stroke group. 2518 (37.7%) were
female, and the mean (SD) age was 64.8 012) years. The observed primary outcome event rate in patients with moderate stroke was 7.6% (129
of 1671) for those in the ticagrelor group and 9.1% (150 of 1641) for those in the placebo group (hazard ratio. 0.84:95% Cl.
0.66-1.06); the primary outcome event rate in patients with less severe stroke was 4.7% (158 of 3359) for those in the ticagrelor group and
5.7% (190 of 3312) for those in the placebo group (hazard ratio. 0.82; 95% Cl, 0.66-1.01) (Pfor interaction = .88). Severe bleeding occurred in
8 patients (0.5%) in the ticagrelor group and in 4 patients (0.2%) in the placebo group in those with moderate stroke compared with 16
patients
CONCLUSIONS AND RELEVANCE In this study, patients with a
moderate ischemic stroke had consistent benefit from ticagrelor
plus aspirin vs aspirin alone compared with patients with less
severe ischemic stroke, with no further increase in the risk of
intracranial bleeding or other severe bleeding events.
13. ABSTRACT
Background In patients with a minor ischaemic stroke or transient ischaemic attack (TIA), separate
trials have shown that dual antiplatelet therapy with clopidogrel plus aspirin (cJopidogrel—aspirin) or
ticagrelor plus aspirin (ticagrelor-aspirin) are more effective than aspirin alone in stroke secondary
prevention. However these two sets of combination have not been directly compared. Since clopidogrel
was less effective in stroke patients who were CKP2C79loss-of-function (LOF) allele carriers, whether
ticagrelor-aspirin is clinically superior to clopidogrel— aspirin in this subgroup of patients with stroke is
unclear. Aim To describe the rationale and design considerations of the Clopidogrel in High-risk
patients with Acute Nondisabling Cerebrovascular Events (CHANCE-2) trial.
Design CHANCE-2 is a randomised, double-blind, doubledummy, placebo-controlled, multicentre trial
that compares two dual antiplatelet strategies for minor stroke or TIA patients who are CYP2C19 LOF
allele carriers: ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily on days 2-90)
or clopidogrel (300 mg loading dose on day 1 followed by 75 mg daily on days 2-90), plus open-label
aspirin with a dose of 75-300 mg on day 1 followed by 75 mg daily on day 2-21. All will be followed for
1 year. Study outcomes The primary efficacy outcome is any stroke (ischaemic or haemorrhagic)
within 3 months and the primary safety outcome is any severe or moderate bleeding event within 3
months.
Discussion The CHANCE-2 trial will evaluate whether ticagrelor-aspirin is superior to
clopidogrel—aspirin for minor stroke or TIA patients who are CYP2C19 LOF allele
carriers
CHANCE 2 TRIAL (ONGOING)
16. ECASS III TRIAL .
Werner Hacke, M.D., N/larkku Kaste. M.D., Erich Bluhmki, Ph.D., Miroslav Brozman, M.D., Antoni Divalos, M.D., Donata Guidetti, M.D., Vincent Larrue, M.D., Kennedy
R. Lees, M.D., Zakaria Medeghri, M.D.,
Thomas Machnig, M.D., Dietmar Schneider, M.D., Rudiger von Kummer, M.D., Nils Wahlgren, M.D.,
and Danilo Toni, M.D., for the ECASS Investigators*
ABSTRACT
BACKGROUND
Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after
the onset of symptoms have not been established. We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke.
METHODS
After exclusion of patients with a brain hemorrhage or major infarction, as detected on a computed tomographic scan, we randomly assigned patients with acute ischemic
stroke in a 1:1 double-blind fashion to receive treatment with intravenous alteplase (0.9 mg per kilogram of body weight) or placebo. The primary end point was
disability at 90 days, dichotomized as a favorable outcome (a score of 0 or 1 on the modified Rankin scale, which has a range of 0 to 6, with 0 indicating no symptoms at
all and 6 indicating death) or an unfavorable outcome (a score of 2 to 6 on the modified Rankin scale). The secondary end point w^as a global outcome analysis of four
neurologic and disability scores combined. Safety end points included death, symptomatic intracranial hemorrhage, and other serious adverse events.
RESULTS
We enrolled a total of 821 patients in the study and randomly assigned 418 to the alteplase group and 403 to the placebo group. The median time for the administration of
alteplase was 3 hours 59 minutes. More patients had a favorable outcome with alteplase than with placebo (52.4% vs. 45.2%; odds ratio, 1.34; 95% confidence interval
[CD, 1.02 to 1.76; P=0.04). In the global analysis, the outcome was also improved with alteplase as compared with placebo (odds ratio, 1.28; 95% Cl, 1.00 to 1.65;
P<0.05). The incidence of intracranial hemorrhage was higher with alteplase than with placebo (for any intracranial hemorrhage, 27.0% vs. 17.6%; P=0.001; for
symptomatic intracranial hemorrhage, 2.4% vs. 0.2%; P=0.008). Mortality did not differ significantly between the alteplase and placebo groups (7.7% and 8.4%,
respectively; P=0.68). There was no significant difference in the rate of other serious adverse events.
CONCLUSIONS
As compared with placebo, intravenous alteplase administered between 3 and 4.5 hours
after the onset of symptoms significantly improved clinical outcomes in patients with acute
ischemic stroke; alteplase was more frequently associated with svmptomatic intracranial
hemorrhage.
17. Intensive blood pressure reduction with intravenous
thrombolysis therapy for acute ischaemic stroke
(ENCHANTED): an international, randomised, open-label
blinded-endpoint, phase 3 trial
.
Interpretation Although intensive blood pressure lowering is safe,
the observed reduction in intracranial haemorrhage did not lead to
improved clinical outcome compared with guideline treatment.
These results might not support a major shift towards this treatment
being applied in those receiving alteplase for mild-to-moderate
acute ischaemic stroke. Further research is required to define the
underlying mechanisms of benefit and harm resulting from early
intensive blood pressure lowering in this patient group.
18. Tenecteplase versus Alteplase before Thrombectomy
EXTEND-1A TNK TRIAL
METHODS
We randomly assigned patients with ischemic stroke who had occlusion of the internal carotid, basilar, or
middle cerebral artery and who were eligible to undergo thrombectomy to receive tenecteplase (at a dose
of 0.25 mg per kilogram of body weight; maximum dose, 25 mg) or alteplase (at a dose of 0.9 mg per
kilogram; maximum dose, 90 mg) within 4.5 hours after symptom onset. The primary outcome was
reperfusion of greater than 50% of the involved ischemic territory or an absence of retrievable thrombus
at the time of the initial angiographic assessment. Noninferiority of tenecteplase was tested, followed by
superiority. Secondary outcomes included the modified Rankin scale score (on a scale from 0 [no
neurologic deficit] to 6 [death]) at 90 days. Safety outcomes were death and symptomatic intracerebral
hemorrhage.
RESULTS
Of 202 patients enrolled, 101 were assigned to receive tenecteplase and 101 to receive alteplase. The
primary outcome occurred in 22% of the patients treated with tenecteplase versus 10% of those treated
with alteplase (incidence difference, 12 percentage points;
95% confidence interval [Cl], 2 to 21; incidence ratio, 2.2; 95% Cl, 1.1 to 4.4; P=0.002 for
noninferiority; P=0.03 for superiority). Tenecteplase resulted in a better 90-day functional outcome than
alteplase (median modified Rankin scale score, 2 vs. 3; common odds ratio, 1.7; 95% Cl, 1.0 to 2.8;
P=0.04). Symptomatic intracerebral hemorrhage occurred in 1% of the patients in each group.
CONCLUSIONS
Tenecteplase before thrombectomy was associated with a higher
incidence of reperfusion and better functional outcome than
alteplase among patients with ischemic stroke treated within 4.5
hours after symptom onset.
20. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
WAKE-UP TRIAL
BACKGROUND
Under current guidelines, intravenous thrombolysis is used to treat acute stroke only if ' it can be ascertained that the time
since the onset of symptoms was less than 4.5 hours. 1 We sought to determine whether patients with stroke with an unknown
time of onset ! and features suggesting recent cerebral infarction on magnetic resonance imaging i (MRI) would benefit from
thrombolysis with the use of intravenous alteplase.
I
METHODS I
In a multicenter trial, we randomly assigned patients who had an unknown time of onset of stroke to receive either
intravenous alteplase or placebo. All the patients had an ischemic lesion that was visible on MRI diffusion-weighted imaging
but no parenchymal hyperintensity on fluid-attenuated inversion recovery (FLAIR), which • indicated that the stroke had
occurred approximately within the previous 4.5 hours, i We excluded patients for whom thrombectomy was planned. The
primary end point was favorable outcome, as defined by a score of 0 or 1 on the modified Rankin scale of neurologic
disability (which ranges from 0 [no symptoms] to 6 [death]) at 90 days. 1 A secondary outcome was the likelihood that
alteplase would lead to lower ordinal scores on the modified Rankin scale than would placebo (shift analysis).
RESULTS
The trial was stopped early owing to cessation of funding after the enrollment of 503 of an anticipated 800 patients. Of
these patients, 254 were randomly assigned to receive alteplase and 249 to receive placebo. A favorable outcome at 90 days
was reported in 131 of 246 patients (53.3%) in the alteplase group and in 102 of 244 patients (41.8%) in the placebo group
(adjusted odds ratio, 1.61; 95% confidence interval [Cl], 1.09 to 2.36; P=0.02). The median score on the modified Rankin
scale at 90 days was 1 in the alteplase group and 2 in the placebo group (adjusted common odds ratio, 1.62; 95% Cl, 1.17 to
2.23; P=0.003). There were 10 deaths (4.1%) in the alteplase group and 3 (1.2%) in the placebo group (odds ratio, 3.38;
95% Cl, 0.92 to 12.52;
P=0.07). The rate of symptomatic intracranial hemorrhage was 2.0% in the alteplase group and 0.4% in the placebo group
(odds ratio, 4.95; 95% Cl, 0.57 to 42.87; P=0.15).
CONCLUSIONS
In patients with acute stroke with an unknown time of onset, intravenous
alteplase guided by a mismatch between diffusion-weighted imaging and
FLAIR in the region of ischemia resulted in a significantly better functional
outcome and numerically more intracranial hemorrhages than placebo at 90
days.
21. Thrombolysis Guided by Perfusion Imaging up to 9 HoursEXTEND
BACKGROUND
The time to initiate intravenous thrombolysis for acute ischemic stroke is generally limited to within
4.5 hours after the onset of symptoms. Some trials have suggested that the treatment window may
be extended in patients who are shown to have ischemic but not yet infarcted brain tissue on
imaging.
METHODS
We conducted a multicenter, randomized, placebo-controlled trial involving patients with ischemic
stroke who had hypoperfused but salvageable regions of brain detected on automated perfusion
imaging. The patients were randomly assigned to receive intravenous alteplase or placebo between
4.5 and 9.0 hours after the onset of stroke or on awakening with stroke (if within 9 hours from the
midpoint of sleep). The primary outcome was a score of 0 or 1 on the modified Rankin scale, on
which scores range from 0 (no symptoms) to 6 (death), at 90 days. The risk ratio for the primary
outcome was adjusted for age and clinical severity at baseline.
RESULTS
After 225 of the planned 310 patients had been enrolled, the trial was terminated because of a loss
of equipoise after the publication of positive results from a previous trial. A total of 113 patients
were randomly assigned to the alteplase group and 112 to the placebo group. The primary outcome
occurred in 40 patients (35.4%) in the alteplase group and in 33 patients (29.5%) in the placebo
group (adjusted risk ratio, 1.44; 95% confidence interval [Cl], 1.01 to 2.06; P=0.04). Symptomatic
intracerebral hemorrhage occurred in 7 patients (62%) in the alteplase group and in 1 patient (0.9%)
in the placebo group (adjusted risk ratio, 7.22; 95% Cl, 0.97 to 53.5; P=0.05). A secondary ordinal
analysis of the distribution of scores on the modified Rankin scale did not show a significant
between-group difference in functional improvement at 90 days.
CONCLUSIONS
Among the patients in this trial who had ischemic stroke and
salvageable brain tissue, the use of alteplase between 4.5 and
9.0 hours after stroke onset or at the time the patient awoke
with stroke symptoms resulted in a higher percentage of
patients with no or minor neurologic deficits than the use of
placebo. There were more cases of symptomatic cerebral
hemorrhage in the alteplase group than in the placebo group.
22.
23. MECHANICAL
THROMBECTOMY
The stroke physician community witnessed a major “breakthrough” in acute stroke
therapeutics when the results of the first of the many positive trials, “MR CLEAN,”
were published showing a significant absolute benefit in favor of mechanical
thrombectomy in patients with large vessel occlusion (LVO).
Based on the initial studies, the American Stroke Association amended the 2013
guidelines in 2015 to include mechanical thrombectomy as the standard of care in
patients with LVO presenting within six hours. Thereafter, the investigators of
ESCAPE, SWIFT PRIME, REVASCAT, THRACE, and PISTE concluded the same.
The horizon was further expanded when two major landmark trials, DAWN and
DEFUSE 3, established the benefit of mechanical thrombectomy in the delayed
window period in a select group of patients. It further led to the inclusion of the
delayed window period treatment strategies in the 2018 guidelines.
24. Multicenter
Randomized
Clinical Trial of
The NEW ENGLAND
JOURNAL of MEDICINE
ESTABLISH HD IN 1*12 JANUARY 1, 201S VOL 372 NO. 1
A Randomized Trial of Intraarterial Treatment for Acute
Ischemic Stroke
BACKGROUND
Endovascular
Treatment for
Acute Ischemic
Stroke in the
Netherlands (MR
CLEAN)
In patients with acute ischemic stroke caused by a proximal intracranial arterial
occlusion, intraarterial treatment is highly effective for emergency revascularization.
However, proof of a beneficial effect on functional outcome is lacking.
METHODS
We randomly assigned eligible patients to either intraarterial treatment plus usual
care or usual care alone. Eligible patients had a proximal arterial occlusion in the
anterior cerebral circulation that was confirmed on vessel imaging and that could be
treated intraarterially within 6 hours after symptom onset. The primary outcome was
the modified Rankin scale score at 90 days; this categorical scale measures
functional outcome, with scores ranging from 0 (no symptoms) to 6 (death). The
treatment effect was estimated with ordinal logistic regression as a common odds
ratio, adjusted for prespecified prognostic factors. The adjusted common odds ratio
measured the likelihood that intraarterial treatment would lead to lower modified
Rankin scores, as compared with usual care alone (shift analysis).
RESULTS
We enrolled 500 patients at 16 medical centers in the Netherlands (233 assigned to
intraarterial treatment and 267 to usual care alone). The mean age was 65 years
(range, 23 to 96), and 445 patients (89.0%) were treated with intravenous altcplase
before randomization. Retrievable stents were used in 190 of the 233 patients
(81.5%) assigned to intraarterial treatment. The adjusted common odds ratio was
1.67 (95% confidence interval [CD, L21 to 2.30). There was an absolute difference
of 13.5 percentage points (95% Cl, 5.9 to 21.2) in the rate of functional
independence (modified Rankin score, 0 to 2) in favor of the intervention (32.6%
vs. 19.1%). There were no significant differences in mortality or the occurrence of
symptomatic intracerebral hemorrhage.
In patients with acute ischemic stroke caused by a proximal intracranial occlusion
of the anterior circulation, intraarterial treatment administered within 6 hours after
stroke onset was effective and safe.
25. Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PAAlone
in Stroke SWIFT-PRIME
BACKGROUND
Among patients with acute ischemic stroke due to occlusions in the proximal ante- ' rior intracranial
circulation, less than 40% regain functional independence when ' treated with intravenous tissue
plasminogen activator (t-PA) alone. Thrombectomy N with the use of a stent retriever, in addition to
intravenous t-PA, increases reperfu- < sion rates and may improve long-term functional outcome. .
METHODS (
We randomly assigned eligible patients with stroke who were receiving or had re- , ceived intravenous
t-PA to continue with t-PA alone (control group) or to undergo endovascular thrombectomy with the
use of a stent retriever within 6 hours after symptom onset (intervention group). Patients had
confirmed occlusions in the proximal anterior intracranial circulation and an absence of large
ischemic-core lesions.
The primary outcome was the severity of global disability at 90 days, as assessed by . means of the
modified Rankin scale (with scores ranging from 0 [no symptoms] to 6 [death]).
i
RESULTS I
The study was stopped early because of efficacy. At 39 centers, 196 patients under- < went
randomization (98 patients in each group). In the intervention group, the median time from qualifying
imaging to groin puncture was 57 minutes, and the rate of substantial reperfusion at the end of the
procedure was 88%. Thrombectomy with the stent retriever plus intravenous t-PA reduced disability at
90 days over the entire range of scores on the modified Rankin scale (PcO.OOl). The rate of functional
independence (modified Rankin scale score, 0 to 2) was higher in the intervention group than in the
control group (60% vs. 35%, P<0.001). There were no significant between-group differences in 90-day
mortality (9% vs. 12%, P=0.50) or symptomatic intracranial hemorrhage (0% vs. 3%, P=0.12).
In patients receiving intravenous t-PA for acute
ischemic stroke due to occlusions in the proximal
anterior intracranial circulation, thrombectomy with
a stent retriever within 6 hours after onset improved
functional outcomes at 90 days
26. Randomized Assessment of Rapid
Endovascular Treatment of Ischemic Stroke ESCAPE TRIAL
BACKGROUND
Among patients with a proximal vessel occlusion in the anterior circulation, 60 to 80% of patients die within 90
days after stroke onset or do not regain functional independence despite alteplase treatment. We evaluated rapid
endovascular treatment in addition to standard care in patients with acute ischemic stroke with a small infarct core,
a proximal intracranial arterial occlusion, and moderate-to-good collateral circulation.
METHODS
We randomly assigned participants to receive standard care (control group) or standard care plus endovascular
treatment with the use of available thrombectomy devices (intervention group). Patients with a proximal
intracranial occlusion in the anterior circulation were included up to 12 hours after symptom onset. Patients with a
large infarct core or poor collateral circulation on computed tomography (CT) and CT angiography were excluded.
Workflow times were measured against predetermined targets. The primary outcome was the score on the
modified Rankin scale (range, 0 [no symptoms] to 6 [death]) at 90 days. A proportional odds model was used to
calculate the common odds ratio as a measure of the likelihood that the intervention would lead to lower scores on
the modified Rankin scale than would control care (shift analysis).
RESULTS
The trial was stopped early because of efficacy. At 22 centers worldwide, 316 participants were enrolled, of whom
238 received intravenous alteplase (120 in the intervention group and 118 in the control group). In the intervention
group, the median time from study CT of the head to first reperfusion was 84 minutes. The rate of functional
independence (90-day modified Rankin score of 0 to 2) was increased with the intervention (53.0%, vs. 29.3% in
the control group; P<0.001). The primary outcome favored the intervention (common odds ratio, 2.6; 95%
confidence interval, 1.7 to 3.8; P<0.001), and the intervention was associated with reduced mortality (10.4%, vs.
19.0% in the control group; P=0.04). Symptomatic intracerebral hemorrhage occurred in 3.6% of participants in
intervention group and 2.7% of participants in control group (P=0.75).
CONCLUSIONS
Among patients with acute ischemic stroke with a proximal
vessel occlusion, a small infarct core, and moderate-to-good
collateral circulation, rapid endovascular treatment improved
functional outcomes and reduced mortality
27. Thrombectomy within 8 Hours after SvmDtom Onset in
Ischemic Stroke
REVASCAT TRIAL
We aimed to assess the safety and efficacy of thrombectomy for the treatment of stroke
in a trial embedded within a population-based stroke reperfusion registry.
METHODS
During a 2-year period at four centers in Catalonia, Spain, we randomly assigned 206
patients who could be treated within 8 hours after the onset of symptoms of acute
ischemic stroke to receive either medical therapy (including intravenous al-teplase when
eligible) and endovascular therapy with the Solitaire stent retriever (thrombectomy
group) or medical therapy alone (control group). All patients had confirmed proximal
anterior circulation occlusion and the absence of a large infarct on neuroimaging. In all
study patients, the use of alteplase either did not achieve revascularization or was
contraindicated. The primary outcome was the severity of global disability at 90 days, as
measured on the modified Rankin scale (ranging from 0 [no symptoms] to 6 [death]).
Although the maximum planned sample size was 690, enrollment was halted early
because of loss of equipoise after positive results for thrombectomy were reported from
other similar trials.
RESULTS
Thrombectomy reduced the severity of disability over the range of the modified Rankin
scale (adjusted odds ratio for improvement of 1 point, 1.7; 95% confidence interval [Cl],
1.05 to 2.8) and led to higher rates of functional independence (a score of 0 to 2) at 90
days (43.7% vs. 28.2%; adjusted odds ratio, 2.1; 95% Cl, 1.1 to 4.0). At 90 days, the rates
of symptomatic intracranial hemorrhage were 1.9% in both the thrombectomy group and
the control group (P=1.00), and rates of death were 18.4% and 15.5%, respectively
(P=0.60). Registry data indicated that only eight patients who met the eligibility criteria
were treated outside the trial at participating hospitals.
Among patients with anterior circulation stroke who could be treated
within 8 hours after symptom onset, stent retriever thrombectomy reduced
the severity of poststroke disability and increased the rate of functional
independence.
28. DELAYED WINDOW PERIOD: HOW WIDE IS THE
WINDOW?
To address the question if patients could be treated in the later time
windows, two landmark thrombectomy trials, namely DAWN and
DEFUSE 3, were conducted.
Until these two trials, it was believed that time was one of the most
crucial factor in determining the outcome following MT
late window trials included only those patients who had a small core
and were slow progressors.
based on the above two trials, the American Stroke Association
recommended MT in selected patients with AIS within 6 to 16 hours
of last known normal who have LVO in the anterior circulation and
meet other DAWN or DEFUSE 3 eligibility criteria.
29. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch
between Deficit and Infarct
BACKGROUND
The effect of endovascular thrombectomy that is performed more than 6 hours after the
onset of ischemic stroke is uncertain. Patients with a clinical deficit that is
disproportionately severe relative to the infarct volume may benefit from late
thrombectomy.
METHODS
We enrolled patients with occlusion of the intracranial internal carotid artery or proximal
middle cerebral artery who had last been known to be well 6 to 24 hours earlier and who
had a mismatch between the severity of the clinical deficit and the infarct volume, with
mismatch criteria defined according to age (<80 years or £80 years). Patients were
randomly assigned to thrombectomy plus standard care (the thrombectomy group) or to
standard care alone (the control group). The coprimary end points were the mean score
for disability on the utility-weighted modified Rankin scale (which ranges from 0 [death]
to 10 [no symptoms or disability]) and the rate of functional independence (a score of 0,
1, or 2 on the modified Rankin scale, which ranges from 0 to 6, with higher scores
indicating more severe disability) at 90 days.
RESULTS
A total of 206 patients were enrolled; 107 were assigned to the thrombectomy group and
99 to the control group. At 31 months, enrollment in the trial was stopped because of the
results of a prespecified interim analysis. The mean score on the utility-weighted
modified Rankin scale at 90 days was 5.5 in the thrombectomy group as compared with
3.4 in the control group (adjusted difference [Bayesian analysis], 2.0 points; 95% credible
interval, 1.1 to 3.0; posterior probability of superiority, >0.999), and the rate of functional
independence at 90 days was 49% in the thrombectomy group as compared with 13% in
the control group (adjusted difference, 33 percentage points; 95% credible interval, 24 to
44; posterior probability of superiority, >0.999). The rate of symptomatic intracranial
hemorrhage did not differ significantly between the two groups (6% in the thrombectomy
group and 3% in the control group, P=0.50), nor did 90-day mortality (19% and 18%,
respectively; P=1.00).
Among patients with acute stroke who had last been known to be well 6 to 24
hours earlier and who had a mismatch between clinical deficit and infarct,
outcomes for disability at 90 days were better with thrombectomy plus
standard care than with standard care alone.
DAWN TRIAL
30. Presenting 6 to 24 hours after they were last known to be well
Clinical infarct mismatch was defined as mismatch between
the volume of the ischemic core on CT perfusion imaging and
clinical deficit as measured by National Institutes of Health
Stroke Scale (NIHSS) and categorized according to the age as
follows:
1) Age ≥ 80 y; NIHSS ≥ 10; Ischemic core <21 mL
2) Age < 80 y, NIHSS ≥ 10; Ischemic core <31 mL
3) Age <80 y, NIHSS ≥ 20; 31≤ Ischemic core<51 mL
DAWN TRIAL
31. Thrombectomy for Stroke at 6 to 16 Hours with
Selection by Perfusion Imaging
BACKGROUND
Thrombectomy is currently recommended for eligible patients with stroke who are
treated within 6 hours after the onset of symptoms.
METHODS
We conducted a multicenter, randomized, open-label trial, with blinded outcome assessment, of thrombectomy in
patients 6 to 16 hours after they were last known to be well and who had remaining ischemic brain tissue that was not
yet infarcted. Patients with proximal middle-cerebral-artery or intemal-carotid-artery occlusion, an initial infarct size of
less than 70 ml, and a ratio of the volume of ischemic tissue on perfusion imaging to infarct volume of 1.8 or more
were randomly assigned to endovascular therapy (thrombectomy) plus standard medical therapy (endovascular-therapy
group) or standard medical therapy alone (medical-therapy group). The primary outcome was the ordinal score on the
modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability) at day 90.
RESULTS
The trial was conducted at 38 U.S. centers and terminated early for efficacy after 182 patients had undergone
randomization (92 to the endovascular-therapy group and 90 to the medical-therapy group). Endovascular therapy plus
medical therapy, as compared with medical therapy alone, was associated with a favorable shift in the distribution of
functional outcomes on the modified Rankin scale at 90 days (odds ratio, 2.77; P<0.001) and a higher percentage of
patients who were functionally independent, defined as a score on the modified Rankin scale of 0 to 2 (45% vs. 17%,
P<0.001). The 90-day mortality rate was 14% in the endovascular-therapy group and 26% in the medical-therapy group
(P=0.05), and there was no significant between-group difference in the frequency of symptomatic intracranial
hemorrhage (7% and 4%, respectively; P=0.75) or of serious adverse events (43% and 53%, respectively; P=0.18).
CONCLUSIONS
Endovascular thrombectomy for ischemic stroke 6 to 16 hours
after a patient was last known to be well plus standard medical
therapy resulted in better functional outcomes than standard
medical therapy alone among patients with proximal middle-
cerebral-artery or intemal-carotid-artery occlusion and a region
of tissue that was ischemic but not yet infarcted.
DEFUSE3 TRIAL
32. presenting 6 to 16 hours after they were last known to be well,
with a region of tissue on imaging that was ischemic but not yet
infarcted and fulfilling the criteria for target mismatch (TMM) as
follows:
1) Ischemic core volume (by CT perfusion imaging) <70 mL
2) Mismatch ratio ≥ 1.8
3) an absolute volume of potentially reversible ischemia
(penumbra) of 15 ml or more
DEFUSE 3 TRIAL
33.
34. Endovascular Thrombectomy with or without Intravenous
Alteplase in Acute Stroke DIRECT-MT TRIAL
BACKGROUND
In acute ischemic stroke, there is uncertainty regarding the benefit and risk of administering
intravenous alteplase before endovascular thrombectomy.
METHODS
We conducted a trial at 41 academic tertiary care centers in China to evaluate endovascular
thrombectomy with or without intravenous alteplase in patients with acute ischemic stroke.
Patients with acute ischemic stroke from large-vessel occlusion in the anterior circulation were
randomly assigned in a 1:1 ratio to undergo endovascular thrombectomy alone (thrombectomy-
alone group) or endovascular thrombectomy preceded by intravenous alteplase, at a dose of 0.9
mg per kilogram of body weight, administered within 4.5 hours after symptom onset
(combination-therapy group). The primary analysis for non inferiority assessed the between-
group difference in the distribution of the modified Rankin scale scores (range, 0 [no symptoms]
to 6 [death]) at 90 days on the basis of a lower boundary of the 95% confidence interval of the
adjusted common odds ratio equal to or larger than 0.8. We assessed various secondary
outcomes, including death and reperfusion of the ischemic area.
RESULTS
Of 1586 patients screened, 656 were enrolled, with 327 patients assigned to the thrombectomy-
alone group and 329 assigned to the combination-therapy group.
Endovascular thrombectomy alone was noninferior to combined intravenous alteplase and
endovascular thrombectomy with regard to the primary outcome (adjusted common odds ratio,
1.07; 95% confidence interval, 0.81 to 1.40; P=0.04 for non inferiority) but was associated with
lower percentages of patients with successful reperfusion before thrombectomy (2.4% vs. 7.0%)
and overall successful reperfusion (79.4% vs. 84.5%). Mortality at 90 days was 17.7% in the
thrombectomy-alone group and 18.8% in the combination-therapy group.
CONCLUSIONS
In Chinese patients with acute ischemic stroke from large-
vessel occlusion, endovascular thrombectomy alone was
noninferior with regard to functional outcome, within a 20%
margin of confidence, to endovascular thrombectomy
preceded by intravenous alteplase administered within 4.5
hours after symptom onset.
36. CRYTOGENIC STROKE
Cryptogenic stroke comprises up to 33% of all ischemic strokes.
It is a heterogeneous group because it includes patients with multiple high-risk
causes and those with no cause identified.
majority of cryptogenic strokes appear embolic in nature-led to the refined
definition of embolic stroke of undetermined source (ESUS).
ESUS is a subset of cryptogenic stroke and refers to an embolic-appearing
stroke for which no high-risk cause has been determined despite a thorough
diagnostic workup (including at least 24 hours of cardiac rhythm monitoring)
.
ESUS patients are heterogeneous, including some with later atrial fibrillation
and some with nonstenotic carotid plaques
37. If this diagnostic testing has not yielded a high-risk cause, detailed evaluation
needed:
1. Extended cardiac monitoring:
EMBRACE (Event Monitor Belt for Recording Atrial Fibrillation After a
Cerebral Ischemic Event): detection of 30 seconds of AF was achieved in
3.2% of patients with usual care(including an electrocardiography and inpatient
cardiac telemetry) and 16.1% of those who wore an extended cardiac monitor.
(30-day cardiac event monitor)
CRYSTAL-AF (Cryptogenic Stroke and Underlying AF) 1.4% of
patients were found to have AF within 6 months while 8.9% of those in the
insertable cardiac monitor group were found to have AF. At 3 years of
follow-up, detection of AF exceeded 30%.
38. 2. Transesophageal echocardiography (TEE):
• TEE provides more detailed imaging than transthoracic echocardiography
especially of the left atrium, left atrial appendage, valvular structures, and
the arch of the aorta.
• examine for the presence of left atrial/ atrial appendage thrombus, atrial
myxoma, fibroelastoma, or vegetation.
• It may also be used if PFO is suspected or further detail is required on its
morphology.
• TEE is reserved for patients the below the age of 60 as the yield of this test
is low above that threshold.
39. 3. Hypercoagulability testing:
should be considered in a person with no other candidate cause
identified especially if they have a history of arterial thrombotic events
elsewhere or a family history of arterial thrombotic events.
4. Other:
MRI with T1 fat-suppressed sequences (to examine for arterial
dissection not visible on previous testing), diagnostic cerebral angiography,
and cerebrospinal fluid testing (if cerebral vasculitis or reversible cerebral
vasoconstriction are suspected) or genetic testing (if an inherited stroke
syndrome is suspected).
Additional considerations include emerging putative associations with ESUS
including occult malignancy, the carotid web,
and nonstenotic carotid atherosclerosis within the early phases of a patient’s
diagnostic workup.
40. Ischemic stroke or TIA
24-hour cardiac
monitoring
Vascular
imaging
Echocardiography Neuroimaging
L J
ESUS
(non-lacunar)
Prolonged cardiac
monitoring
CRYPTOGENIC STROKE
No cardioembolic mechanisms
No large vessel stenosis >S0%
No small vessel occlusion* No
other causes
ARCADIA DEFINITION FOR
LACUNAR STROKE
Both criteria should be met:
1) Subcortical (Including pons and
mtdbrain) Infarct In the distribution
of small penetrating arteries.
2) <1.5 cm on CT or T2-MRI.
or <2.0 cm on DWI MRI
Lacunar
Atrial cardiopathy or
systemic embolism
Yes No
Carotid Complex Nonstenotic
Web aortic plaque carotid plaque PFO
Occult or
known
cancer
Atrial Cardiopathy
ARCADIA0«f INITION fOR A TRIAL CAR
OTOPATHY (any of the following)
1} PTFV1>5000 mV/rm on 12 lead ECG
2) Serum NT proBNP >2 SO pg/ml
3) Left atrial diameter index
>3 cm/mJ on echocardiogram
Antiplatelet agents
Statins
Anticoagulants
Cancer therapy
Antiplatelet agents and wait
for ARCADIA & ATTICUS
Antiplatelet agents
Statins
41. The distinction between ESUS and lacunar cryptogenic stroke is sometimes
challenging.
ARCADIA (Atrial Cardiopathy and Antithrombotic Drugs in
Prevention After Cryptogenic Stroke) randomized clinical trial
provide a simple and clinically sound criteria.
According to the ARCADIA criteria, lacunar cryptogenic strokes are those
involving subcortical cerebral territories of small penetrating arteries,
including the pons and midbrain.
The established size of lacunar infarcts is <1.5 cm on CT or T2-MRI or
<2.0 cm on diffusion-weighted imaging MRI.
Embolic infarcts are those involving the cerebral cortex, multiple small
subcortical infarcts occurring simultaneously in the same or different
vascular territories, lateral medullary infarcts, or cerebellar infarcts.
43. • one of the most common cause of ischemic stroke worldwide, causing up to
50% of ischemic strokes in Asia
• high risk of recurrence
• WASID study (Warfarin-Aspirin Symptomatic Intracranial Disease)
evaluated patients with a stroke or TIA in the previous 90days due to
intracranial stenosis of 50% to 99% and found a 19% risk of recurrent
ischemic stroke at 2 years, with 75% occurring in the distribution of the
stenotic artery.
44. Antithrombotic Treatment
mainstay of management for secondary prevention in ICAD.
Anticoagulants- tested in the WASID trial found not effective;
patients treated with warfarin to a goal INR 2 to 3 had a similar rate of stroke
recurrence than those on aspirin but a higher rate of
major hemorrhagic events and death.
DAPT - standard of care for the initial 3 months after an index event.
SAMMPRIS trial (Stenting Versus Aggressive Medical Therapy for
Intracranial Arterial Stenosis),
enrolled a higher risk population with 70% to 99% stenosis within 30 days on
stroke onset treated with aspirin
and clopidogrel, and a similar high-risk cohort from WASID, suggested that
DAPT for 90 days was superior to aspirin in preventing recurrence in this
earlier period. (THALES and CHANCE trial also)
45. Cilostazol-based regimens of DAPT for ICAD.
CATHARSIS (Cilostazol-Aspirin Therapy Against Recurrent Stroke With
Intracranial Artery Stenosis Study) no benefit of cilostazol plus aspirin versus
aspirin alone
open-label CSPS trial (Cilostazol Stroke Prevention Study for Antiplatelet
Combination), which compared cilostazol plus aspirin or clopidogrel versus
aspirin or clopidogrel alone in patients 8 to 180 days after symptom onset did
find a lower risk of recurrent ischemic stroke
TOSS-2 trial (Trial of Cilostazol in Symptomatic Intra- cranial Arterial
Stenosis II) DAPT with cilostazol plus aspirin versus clopidogrel plus aspirin
was tested in the which enrolled patients with ICAD within 2 weeks; there was
no difference in stroke recurrence in the territory of the symptomatic vessel at 7
months with either regimen.
DAPT did not increase hemorrhagic complications in ICAD studies.
46. Vascular Risk Factor Control
RISK FACTORS- Poorly controlled cholesterol and low-density lipoprotein,
elevated blood pressure (BP) inadequate physical activity
PREVENTION- High-dose statins, engage in at least moderate regular
physical activity, and achieve a systolic BP of <130 mmHg.
BUT the early post- stroke management of BP after an ICAD-related stroke
has not been well studied, and smaller trials have suggested
potential higher risk of aggressive BP control in the early window,
particularly in those with hemodynamic impairment.
47. Revascularization
Endovascular approaches to ICAD - tested in 2 randomized clinical trials with
negative results.
SAMMPRIS trial evaluated high-risk patients with symptoms within 30 days
(median 7 days) with high-grade stenosis and randomized patients to intensive
medical therapy with or without angioplasty and stenting with a self-expanding
stent. It found a greater rate of stroke and death at 30 days of 14.7% in the
intervention arm versus 5.3 in the medical
treatment arm, with no delayed benefit was observed in long-term outcomes
VISSIT trial (Vitesse Stent Ischemic Therapy) utilizing a balloon-mounted stent
found a higher periprocedural risk with endovascular therapy.
angioplasty and stenting should not be recommended as initial treatment of
symptomatic ICAD.
49. Atherosclerotic carotid artery disease : major causes of ischemic stroke and TIA,
accounting for about 10% of cases.
primarily at the carotid bifurcation, involving the distal common and the
proximal internal carotid artery.
previous trials showed: robust benefit of carotid endarterectomy for severe (70%-
99%) stenosis, moderate stenosis (50%-69%), no demonstrable benefit below
50% stenosis.
Early surgery, with revascularization performed within 2 weeks of the last
symptomatic event, is now recommended.
50. • Regarding choice of revascularization procedure, CEA is currently
performed more than CAS, with CEA accounting for >80% of procedures
in a previous national study
• several trials found a lower complication rate with CEA (1.3% rate of
stroke/death) compared to carotid artery stenting (CAS; 8.3%).
• CAS has been associated with a higher complication rate above age 70
years.
• CEA has been associated with a lower rate of periprocedural stroke but a
higher rate of periprocedural myocardial infarction in relation to CAS.
51. Transcarotid artery revascularization (TCAR)- newer revascularization
option
• In this procedure, there is direct access achieved in the common carotid
artery and flow reversal is instituted.
• lower stroke/death rate with TCAR compared to transfemoral CAS.
• ROADSTER 2 (Safety and Efficacy Study for Reverse Flow Used During
Carotid Artery Stenting Procedure 2) registry, the 30-day stroke/death rate
was 5.0% in symptomatic patients and 1.4% in asymptomatic patients.
• No randomized trial comparing TCAR with either CEA or CAS.
• Despite growing enthusiasm for TCAR, the American Heart Association
and American Stroke Association secondary prevention guidelines felt that
the efficacy of TCAR for symptomatic patients is not well established
53. Full spectrum of cerebral SVD includes
• covert cerebral SVD detected incidentally on brain neuroimaging,
• SVD-related clinical presentations with lacunar stroke,
• cognitive decline or dementia,
• mood or physical dysfunction.
Markers of SVD on brain imaging are white matter hyperintensities,
cerebral microbleeds (CMBs), lacunes, and enlarged perivascular
spaces.
54. Antithrombotic Agents in the Context of Ischemic Stroke
Related to SVD
SPS3 trial (Secondary Prevention of Small Subcortical Stroke) of 3020 patients
with lacunar ischemic stroke (mean age 63 years), long-term dual versus single
antiplatelet therapy increased bleeding and death without reducing recurrent
stroke.
The pathological findings in SVD are arteriolosclerosis, lipohyalinosis,
fibrinoid necrosis in which thrombi may not be relevant. So, the usefulness of
antiplatelet agent such as aspirin may be challenged.
the general guidance for noncardioembolic secondary stroke prevention and
the use of antiplatelet therapy also applies for stroke caused by SVD.
55. • In patients with SVD, the balance between the prevention of a recurrent
occlusive event versus the risk of ICH is a major concern.
In a systematic review, cilostazol decreased recurrent ischemic stroke,
hemorrhagic stroke, deaths, systemic bleeding. To date, the usefulness of
cilostazol in non-Asian population in ischemic stroke related to SVD
remains uncertain.
• The 2021 European Stroke Organization guidelines on covert cerebral SVD
concluded that in patients with covert SVD (ie, who did not have any clinical
stroke) antiplatelet agents cannot be recommended to reduce the risk of
future stroke, major adverse cardiovascular events or cognitive decline.
56. Other Pharmacological Interventions BP
Management
In patients with SVD, intensive management of BP is probably the most
effective way to prevent both ischemic and hemorrhagic events as well as
cognitive decline.
Statins
Statins are recommended in secondary prevention guidelines with no evidence
of different effects in lacunar ischemic stroke as hyperlipidemia does not play
an important role in the development of SVD
Lifestyle
physical activity may play an important role in secondary stroke prevention.
58. Table 1. Short-Term and Long-Term Secondary Prevention Strategies With Cardioembolic Stroke Causes
Short-term management Long-term management
ATRIAL FIBRILLATION Oral anticoagulation (prefer DOACs over warfarin)
Oral anticoagulation (prefer DOACs
over warfarin)
Optimal initiation timing is unknown, but reasonable to start 2-14 d from stroke
Left atrial Appendage Occlusion as an alternative to oral
anticoagulation
Avoid bridging with heparin or low molecular weight heparin Avoid concomitant antiplatelet therapy unless strong indication
ATRIAL CARDI- Antiplatelet therapy Antiplatelet therapy
OPATHY Cardiac monitoring to look for AF
Anticoagulation if AF is found on cardiac monitoring
PFO Antithrombotic therapy PFO closure in patients meeting criteria
for positive PFO trials
Thorough investigation including cardiac monitoring to look for competing stroke
mechanisms Antithrombotic therapy in patients not meeting criteria for
positive PFO trials
59. INFECTIVE ENDO- Intravenous antibiotics Warfarin for mechanical heart valve
CARDITIS
Avoid anticoagulation Anticoagulation for concomitant AF
Consideration of surgery Preventative measures to reduce the risk of transient bacteremia
RECENT MYOCAR- Antiplatelet therapy Antiplatelet therapy
DIAL INFARCTION
Cardiac monitoring to look for AF Warfarin for persistent LV thrombus
TTE with Definity or Cardiac MRI to look for LV thrombus
Warfarin for at least 3 mo for LV thrombus
Warfann for at least 3 mo for anterior STEMI with apical
hypokinesis
60. i i IUOIO
LV DYSFUNCTION Antiplatelet therapy Antiplatelet therapy
Cardiac monitoring to look for AF Warfarin for persistent LV thrombus
TTE with Definity or cardiac MRI to look for LV thrombus Anticoagulation treatment if AF is found
Warfann for at least 3 mo for LV thrombus (reasonable Consider anticoagulation with warfarin
to start 4-14 d from stroke) or DOAC patients with EF <15%
Consider anticoagulation with warfann or DOAC patients with EF <15%
RHEUMATIC VAL-
Anticoagulation, preferably with warfarin,
particularfy if
Anticoagulation, preferably with
warfarin
VULAR DISEASE concomitant AF particularly if concomitant AF
Cardiac monitoring to look for AF if not present on initial assessment
Consider valve surgery
Consider initiation at 4-14 d from ischemic stroke
Avoid bridging with heparin or low molecular weight heparin
CARDIAC TUMORS Antithrombotic therapy Antithrombotic therapy
Cardiac monitoring to look for AF if not present on initial Anticoagulation with DOAC or warfann
assessment if concomitant AF
Consider surgical resection when safe from stroke standpoint
61. Stroke
88%
■ INTRACEREBRAL HEMORRHAGE
■ SUBARACHNOID HEMORRHAGE
■ ISCHEMICSTROKE
Ischemic Stroke
■ CARDlOEMBOUC
■ CRYPTOGENIC
LARGE ARTERY
■ OTHER
Cryptogenic Stroke
50%
Figure 1. Conceptual representation of
ischemic stroke subtypes.
Percentages arc approximate ard arc informed
by KoJomirsky-Rabas ct al36 ard Gardcrcr ct
aJ. 'T Precise percentages will ccpcnd on
extent of testirg ard patient populations.
Ischemic stroke subtype ccfiritors arc
informed by the TOAST (Trial o’* Org 10172 m
Acute Stroke Treatment) classification
scheme38 urlcss otherwise incicatcd. ES'JS
indicates embolic stroke of undetermined
source.
50%
■ ESUS
■ NON-ESUS
62. 5.4. Cardioembolism
5.4.1. Atrial Fibrillation
Recommendations for AF
Referenced studies that support recommendations are summarized in online
COR LOE Recommendations
1 A
1. In patients with nonvalvular AF and stroke or TIA, oral anticoagulation (eg,
apixaban, dabi-gatran, edoxaban, rivaroxaban, or warfann) is recommended
to reduce the risk of recurrent stroke.
1 B-R
2. In patients with AF and stroke or TIA, oral anticoagulation is indicated to reduce
the risk of recurrent stroke regardless of whether the AF pattern is paroxysmal,
persistent, or permanent.
1 B-R
3. In patients with stroke or TIA and AF who do not have moderate to severe mitral
stenosis or a mechanical heart valve, apixaban, dabi-gatran, edoxaban, or
rivaroxaban is recommended in preference to warfarin to reduce the risk of
recurrent stroke.
1 B-NR
4. In patients with atrial flutter and stroke or TIA, anticoagulant therapy similar to
that in AF is indicated to reduce the risk of recurrent stroke
63. 1 C-EO
5. In patients with AF and stroke or TIA, without moderate to severe
mitral stenosis or a mechanical heart valve, who are unable to
maintain a therapeutic INR level with warfarin, use of dabigatran,
rivaroxaban, apixaban, or edoxaban is recommended to reduce
the risk of recurrent stroke.
2a B-NR
6. In patients with stroke at high risk of hemorrhagic conversion in
the setting of AF, it is reasonable to delay initiation of oral
anticoagulation beyond 14 days to reduce the risk of ICH/20-*31
2a C-EO
7. In patients with TIA in the setting of nonvalvu-lar AF, it is
reasonable to initiate anticoagulation immediately after the index
event to reduce the risk of recurrent stroke.
64. 5.4.2. Valvular Disease
Recommendations for Valvular Disease
Referenced studies that support recommendations are summarized in online
COR LOE Recommendations
1 B-R
1. In patients with ischemic stroke or TIA and valvular AF
(moderate to severe mitral stenosis or any mechanical
heart valve), warfarin is recommended to reduce the risk of
recurrent stroke or TIA
1 C-LD
2. In patients with a mechanical mitral valve and a history of
ischemic stroke or TIA before valve replacement, aspirin
(75-100 mg/d) is recommended in addition to warfarin with
an I NR target of 3.0 (range, 2.5-3.5) to reduce the risk of
thrombosis and recurrent stroke or TIA
1 C-EO
3. In patients with ischemic stroke or TIA and native aortic or
nonrheumatic mitral valve disease (eg, mitral annular
calcification or mitral valve prolapse) who do not have AF
or another indication for anticoagulation, antiplatelet
therapy is recommended to reduce the risk of recurrent
stroke or TIA.
1 C-EO
4. In patients with a bioprosthetic aortic or mitral valve, a
history of ischemic stroke or TIA before valve replacement,
and no other indication for anticoagulation therapy beyond
3 to 6 months from the valve placement, long-term therapy
with aspirin is recommended in preference to long-term
anticoagulation to reduce the risk of recurrent stroke or
TIA.
65. Figure 3. Recommended antithrombotic regimen in patients with history of ischemic stroke or transient ischemic attack (TIA) and different
valvular heart disease conditions.
Colors correspond to Class of Recommendation in Table 3. Abx indicates antibiotics; AF, atrial fibrillation; AV, aortic valve; AVD, aortic valve disease;
DOAC, direct oral anticoagulant; MAC, mitral annular calcification; MS, mitral stenosis; MV, mitral valve; MVD, mitral valve disease; MVP, mitral valve
prolapse; and VHD, valvular heart disease. 'Definition of valvular AF. t Includes MAC and MVP. * Rheumatic and nonrheumatic AVD. increase the target
international normalized ratio by 0.5, depending on bleeding risk.